Generic pharmaceuticals now account for more than 90% of all prescriptions issued in the United States. However, the generic pharmaceuticals’ pipeline flow is anything but smooth. A report issued on Aug. 7, 2019 by the US Government Accountability Office (GAO) (1) traces part of the problem to issues with FDA review. A New Prior Knowledge” concept that would make crucial process and product information available has been proposed by the National Institute for Pharmaceutical Technology and Education.

, September 2019
	September 2019
	Pages: 24–26

	When referring to this article, please cite it as A. Shanley, “Generics: Getting Beyond ‘File First, Figure it Out Later’," 

Pharmaceutical Technology Regulatory Sourcebook

Development

Dosage Forms

Generic Drugs

Quality Assurance/Quality Control

Quality by Design

Quality Systems

Regulatory Authority Actions

Regulatory Filings and Submissions

Regulatory/GMP Compliance

Pharmaceutical Technology-09-15-2019

A GAO report analyzes some of the reasons why so few generics are approved the first time around. NIPTE has proposed a program that would address these issues. 